LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 25, 2005--Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) today announced the initiation of a large, international Phase III clinical trial of PRO 2000, the Company’s topical, vaginal microbicide in development for the prevention of sexually transmitted infections, including HIV, herpes, chlamydia and gonorrhea. The trial is being sponsored by the Medical Research Council of the United Kingdom (MRC) and conducted by the UK Government-funded Microbicides Development Programme (MDP).
